Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $42.43 and traded as high as $46.28. Global X Genomics & Biotechnology ETF shares last traded at $46.24, with a volume of 14,239 shares.

Global X Genomics & Biotechnology ETF Stock Up 0.2%

The stock’s fifty day simple moving average is $47.30 and its 200-day simple moving average is $42.43. The company has a market capitalization of $50.40 million, a PE ratio of -19.76 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently disclosed a dividend, which was paid on Wednesday, January 7th. Investors of record on Tuesday, December 30th were paid a $0.5912 dividend. This represents a yield of 259.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is presently -26.50%.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several large investors have recently bought and sold shares of GNOM. Flow Traders U.S. LLC increased its position in shares of Global X Genomics & Biotechnology ETF by 52.4% in the second quarter. Flow Traders U.S. LLC now owns 238,725 shares of the company’s stock valued at $2,012,000 after buying an additional 82,063 shares in the last quarter. Jane Street Group LLC increased its holdings in Global X Genomics & Biotechnology ETF by 7.7% during the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after acquiring an additional 10,308 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Global X Genomics & Biotechnology ETF by 8.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock worth $756,000 after acquiring an additional 6,708 shares during the last quarter. Insight Advisors LLC PA raised its position in Global X Genomics & Biotechnology ETF by 47.9% during the second quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock worth $503,000 after acquiring an additional 19,319 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares in the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.